MINISTRY-FOREIGN-JAPAN
On February 19th, representatives of the governments of Japan and Ukraine, as well as business organizations, gathered in Tokyo for the Japan-Ukraine Conference for Promotion of Economic Growth and Reconstruction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229458562/en/
Prime Minister Kishida Fumio emphasized how Japan can contribute to Ukraine’s post-war reconstruction. (Photo by: Cabinet Public Affairs Office)
The Japanese government delegation, led by Prime Minister of Japan Kishida Fumio, pledged long-term support for Ukraine's recovery through public-private partnership. The Ukrainian delegation, led by Prime Minister of Ukraine Denys Shmyhal, thanked Japan for its assistance and invited Japanese businesses to invest in Ukraine's reconstruction. Each delegation consisted of more than 100 government and corporate officials. In total, around 300 people and 130 companies took part in the conference. The two governments agreed to cooperate on seven key areas: land mine action and debris clearance, humanitarian aid and livelihood reconstruction, agricultural development, biotechnology, digital and information technology, transportation and energy infrastructure, and anti-corruption and governance-strengthening measures.
In his keynote speech, Prime Minister Kishida described supporting Ukraine's recovery from the ongoing war as "investing in the future," and called on the international community to contribute. “Japan’s public and private sectors will all work together through an all-Japan approach, utilizing the knowledge derived from Japan’s postwar and disaster reconstruction efforts,” he said in his speech. “The promotion of economic reconstruction, however, is not only investment for the future of Ukraine but also investing in Japan and the whole globe.” He outlined new initiatives for Japan's public and private sectors to support Ukraine. Kishida also announced that Japan would ease entry visa requirements for Ukrainian citizens involving in Japan-Ukraine cooperation projects.
Prime Minister Shmyhal thanked Japan for its ongoing assistance and Prime Minister Kishida for his visit to Ukraine in 2023. He added “Today’s conference will be the next step towards continuing the development of both countries’ relationships.” Shmyhal mentioned the financial success of Japanese companies in Ukraine so far and invited businesses to further invest in the coming “Ukrainian economic miracle.” He underlined key sectors such as energy, agriculture, and infrastructure as offering prime investment opportunities with robust growth potential.
Both leaders emphasized their commitment to cooperation, as well as the importance of the private sector in Ukraine's reconstruction.
The conference resulted in the announcement of 56 documents, including inter-governmental agreements. The two governments signed a convention eliminating double taxation, which will support Japanese companies to invest in Ukraine. They also signed an agreement on bilateral crediting, exchanged notes concerning a grant aid for emergency recovery, and pledged to collaborate in the fields of education and technology.
Other documents included deals between government agencies and individual businesses and business organizations. Japanese companies signed deals with Ukrainian companies and government agencies to develop energy facilities, rebuild infrastructure, remove land mines, and more.
Since the Russian invasion in February 2022, Japan has consistently provided humanitarian aid and other assistance to Ukraine. With the public-private partnership announced at this conference, Japan plans to use its technological expertise and experience in post-disaster recovery and reconstruction to strengthen its support for Ukraine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229458562/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
